作为具有神经保护性质的有前途的药物,JNK3抑制剂
Yibeini Wu1, Yiling Zhao2, Ziman Guan1
1Department of Anatomy and Developmental biology, Monash University, Clayton, Vic, Australia.
Cell adhesion & migration
|February 15, 2024
概括
针对C-Jun N-终端激酶3 (JNK3) 的神经保护疗法在中枢神经系统 (CNS) 疾病中表现有前途. 抑制JNK3可能会促进神经元在各种神经系统疾病中的修复.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 中枢神经系统 (CNS) 疾病共享神经退行机制,这表明神经保护的广泛治疗潜力.
- 在中枢神经系统中普遍存在的C-Jun N-终端激酶3 (JNK3) 调节大脑发育和记忆等关键功能.
- JNK3涉及神经退行性途径,使其成为潜在的治疗点.
研究的目的:
- 审查与中枢神经系统疾病相关的关键神经保护机制.
- 探索神经退行性疾病和神经保护策略之间的关系.
- 讨论用于神经保护的JNK3抑制剂的发展.
主要方法:
- 文献综述侧重于神经保护和JNK3.
- 分析JNK3在神经退行症中的作用.
- 检查小分子JNK3抑制剂的发展.
主要成果:
- 分享的神经退行性路径为神经保护提供了一个统一的目标.
- JNK3在中枢神经系统生理学和病理学中发挥着重要作用.
- 小分子JNK3抑制剂正在成为潜在的神经保护剂.
结论:
- 向JNK3为开发新型神经保护疗法提供了一个有希望的途径.
- 在中枢神经系统疾病中,JNK3抑制剂可能有助于神经元恢复和自我修复.
- 进一步开发JNK3抑制剂可能会促进多种神经系统疾病的治疗.
关键词:
细胞灭亡 (apoptosis) 是一种死亡的过程.在JNK3中,JNK3是最常见的.MAPK信号通道的信号通道抑制剂抑制剂的使用神经退行性疾病是一种神经退行性疾病.神经炎症是一种神经炎症.神经保护神经保护氧化应激是一种氧化应激.更多相关视频
08:23Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
Published on: August 9, 2014
11.4K
06:34New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells
Published on: October 9, 2017
9.1K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K